News

Net profit of Tata Elxsi rose 18.17% to Rs 170.60 crore in the quarter ended June 2026 as against Rs 144.37 crore during the previous quarter ended June 2025. Sales rose 14.46% to Rs 1021.11 crore in the quarter ended June 2026 as against Rs 892.10 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales1021.11892.10 14 OPM %21.1520.93 - PBDT254.72220.62 15 PBT232.45196.35 18 NP170.60144.37 18 Powered by Capital Market - Live News

Tata Elxsi has allotted 2,497 equity shares under ESOP on 01 July 2026. Consequent to this allotment, the paid-up equity share Capital of the Company stands increased to Rs. 62,29,95,610 divided into 6,22,99,561 equity shares of Rs. 10/- each from Rs. 62,29,70,640 divided into 6,22,97,064 equity shares of Rs. 10/- each.

Tata Elxsi announced that the 37th Annual General Meeting(AGM) of the company will be held on 24 June 2026.

Tata Elxsi announced the launch of AnaTel�, an AI-native software development platform for healthcare and medical technology companies, co-developed with OpenAna, a provider of autonomous AI engineering platforms. AnaTel� makes its debut at DeviceTalks Boston 2026, where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance. Healthcare and medtech software teams face a growing operational challenge. Regulatory expectations for AI-enabled device software are rising, with the FDA`s 2025 draft guidance on AI-Enabled Device Software Functions and Europe`s MDCG 2025-26 both requiring rigorous lifecycle documentation, traceability, and validation evidence as part of core engineering workflows, not submission afterthoughts. The result is a familiar bottleneck: requirements, test cases, traceability matrices, and regulatory artifacts are assembled manually across disconnected tools. Every software change becomes a documentation exercise. Every submission cycle starts from scratch. AnaTel� addresses this by embedding autonomous AI agents directly into the engineering workflow. Unlike developer productivity tools that focus on code generation alone, AnaTel� operates across the full AI-Driven Software Delivery Lifecycle, from requirements and architecture through deployment, verification and validation, and continuous optimization, making it a true end-to-end engineering execution platform for regulated environments. Operating as a configurable AI software team, AnaTel� generates code, documentation, test cases, and regulatory artifacts, drawing on a dedicated Healthcare and Life Sciences expert agent fine-tuned for medtech regulatory and engineering contexts. Human engineers and regulatory experts remain in control at every critical review and decision point. The platform supports eSTAR-aligned submission preparation, requirements traceability matrices, verification and validation evidence, and audit-trail documentation as part of day-to-day engineering. It is expected to reduce SaMD development and change assessment timelines from eight weeks to 72 hours, with productivity improvements of up to 60%. AnaTel� draws on Tata Elxsi`s extensive experience building software in highly regulated medical device environments, engineering depth that has shaped how the platform reasons about traceability, validation, and compliance, not just how it is deployed. Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; OpenAna brings platform and technology innovation.

Tata Elxsi announced the launch of ViTel�, a Material Intelligence solution for Medical Device manufacturers, co developed with Viridium AI, a material intelligence platform company. ViTel� is being formally introduced at DeviceTalks Boston 2026, where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance. Medical device manufacturers are facing a new operating reality. Material decisions now affect margin, resilience, product velocity, and market access, yet critical product knowledge remains buried across BOMs, supplier documents, ERP and PLM systems, and expert teams. This makes every new regulation or customer requirement a costly manual exercise. ViTel� addresses this by creating a reusable Material Intelligence layer across the enterprise, helping teams identify material and supplier dependencies, assess country-of-origin and sourcing exposure, evaluate alternatives, and understand where product or material risks affect cost, continuity, or market access. Powered by Viridium AI`s Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models, ViTel� transforms scattered enterprise data into a living product-material knowledge graph connecting products, parts, materials, chemicals, suppliers, regulations, and evidence. ViTel� draws on Tata Elxsi`s three decades of Med-Tech engineering and regulatory expertise, knowledge that has been embedded into how the solution reasons about material risk, compliance, and sourcing decisions, not just how it is deployed. Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; Viridium AI brings platform and technology innovation.